Maternal prescribed opioid analgesic use during pregnancy and associations with adverse birth outcomes: A population-based study

English version

Autoři: Ayesha C. Sujan ^aff001; Patrick D. Quinn ^aff002; Martin E. Rickert ^aff001; Kelsey K. Wiggs ^aff001; Paul Lichtenstein ^aff003; Henrik Larsson ^aff003; Catarina Almqvist ^aff003; A. Sara Öberg ^aff003; Brian M. D’Onofrio ^aff001
Působiště autorů: Department of Psychological & Brain Sciences, Indiana University Bloomington, Bloomington, Indiana, United States of America ^aff001; Department of Applied Health Science, School of Public Health, Indiana University Bloomington, Bloomington, Indiana, United States of America ^aff002; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden ^aff003; School of Medical Sciences, Örebro University, Örebro, Sweden ^aff004; Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden ^aff005; Department of Epidemiology, T.H. Chan School of Public Health, Harvard, Boston, United States of America ^aff006
Vyšlo v časopise: Maternal prescribed opioid analgesic use during pregnancy and associations with adverse birth outcomes: A population-based study. PLoS Med 16(12): e32767. doi:10.1371/journal.pmed.1002980
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002980

Souhrn

Background

Published research on prescribed opioid analgesic (POA) use during pregnancy and birth outcomes is limited in scope and has not adequately adjusted for potential confounding factors. To help address these gaps, we estimated associations between maternal POAs during pregnancy and two adverse birth outcomes using a large population-based dataset, multiple definitions of POA exposure, and several methods to evaluate the influence of both measured and unmeasured confounding factors.

Methods and findings

We obtained data by linking information from several Swedish registers and conducted a retrospective cohort study on a population-based sample of 620,458 Swedish births occurring between 2007 and 2013 (48.6% female; 44.4% firstborn). We evaluated associations between prenatal POA exposure and risk for preterm birth (PTB; <37 gestational weeks) and small for gestational age (SGA; birth weight 2 standard deviations below the expected weight for gestational age or lower). We evaluated the influence of confounding by adjusting for a wide range of measured covariates while comparing exposed and unexposed infants. Additionally, we adjusted for unmeasured confounding factors by using several advanced epidemiological designs. Infants exposed to POAs anytime during pregnancy were at increased risk for PTB compared with unexposed infants (6.4% exposed versus 4.4% unexposed; adjusted odds ratio [OR] = 1.38, 95% confidence interval [CI] 1.31–1.45, p < 0.001). This association was attenuated when we compared POA-exposed infants with acetaminophen-exposed infants (OR = 1.18, 95% CI 1.07–1.30, p < 0.001), infants born to women who used POAs before pregnancy only (OR = 1.05, 95% CI 0.96–1.14, p = 0.27), and unexposed siblings (OR = 0.99, 95% CI 0.85–1.14, p = 0.92). We also evaluated associations with short-term versus persistent POA use during pregnancy and observed a similar pattern of results, although the magnitudes of associations with persistent exposure were larger than associations with any use or short-term use. Although short-term use was not associated with SGA (adjusted OR_{single-trimester} = 0.95, 95% CI 0.87–1.04, p = 0.29), persistent use was associated with increased risk for SGA (adjusted OR_{multiple-trimester} = 1.40, 95% CI 1.17–1.67, p < 0.001) compared with unexposed infants. The association with persistent exposure was attenuated when we used alternative comparison groups (e.g., sibling comparison OR = 1.22, 95% CI 0.60–2.48, p = 0.58). Of note, our study had limitations, including potential bias from exposure misclassification, an inability to adjust for all sources of confounding, and uncertainty regarding generalizability to countries outside of Sweden.

Conclusions

Our results suggested that observed associations between POA use during pregnancy and risk of PTB and SGA were largely due to unmeasured confounding factors, although we could not rule out small independent associations, particularly for persistent POA use during pregnancy.

Klíčová slova:

Birth – Pregnancy – Drug therapy – Analgesics – Opioids – Infants – Sweden – Preterm birth

Zdroje

1. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol. 2014;123(5):997–1002. Epub 2014/05/03. doi: 10.1097/AOG.0000000000000208 PubMed Central PMCID: PMC4020039. 24785852

2. Bateman BT, Hernandez-Diaz S, Rathmell JP, Seeger JD, Doherty M, Fischer MA, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology. 2014;120(5):1216–24. Epub 2014/02/15. doi: 10.1097/ALN.0000000000000172 24525628.

3. Kroll-Desrosiers AR, Skanderson M, Bastian LA, Brandt CA, Haskell S, Kerns RD, et al. Receipt of Prescription Opioids in a National Sample of Pregnant Veterans Receiving Veterans Health Administration Care. Womens Health Issues. 2016;26(2):240–6. doi: 10.1016/j.whi.2015.09.010 WOS:000375058000016. 26549242

4. Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004–2006. Br J Clin Pharmacol. 2008;65(5):653–60. Epub 2008/02/26. doi: 10.1111/j.1365-2125.2008.03102.x 18294334; PubMed Central PMCID: PMC2432474.

5. Epstein RA, Bobo WV, Martin PR, Morrow JA, Wang W, Chandrasekhar R, et al. Increasing pregnancy-related use of prescribed opioid analgesics. Annals of Epidemiology. 2013;23(8):498–503. doi: 10.1016/j.annepidem.2013.05.017 23889859

6. Malek A, Mattison DR. Drugs and Medicines in Pregnancy: The Placental Disposition of Opioids. Current Pharmaceutical Biotechnology. 2011;12(5):797–803. WOS:000290665000012. doi: 10.2174/138920111795470859 21480827

7. Lind JN, Interrante JD, Ailes EC, Gilboa SM, Khan S, Frey MT, et al. Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review. Pediatrics. 2017;139(6). Epub 2017/06/01. doi: 10.1542/peds.2016-4131 28562278; PubMed Central PMCID: PMC5561453.

8. Yazdy MM, Desai RJ, Brogly SB. Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the Literature. J Pediatr Genet. 2015;4(2):56–70. Epub 2016/03/22. doi: 10.1055/s-0035-1556740 26998394; PubMed Central PMCID: PMC4795985.

9. Brennan MC, Rayburn WF. Counseling about risks of congenital anomalies from prescription opioids. Birth Defects Res A Clin Mol Teratol. 2012;94(8):620–5. Epub 2012/08/01. doi: 10.1002/bdra.23064 22847955.

10. Disher T, Gullickson C, Singh B, Cameron C, Boulos L, Beaubien L, et al. Pharmacological Treatments for Neonatal Abstinence Syndrome: A Systematic Review and Network Meta-analysisPharmacological Treatments for Neonatal Abstinence SyndromePharmacological Treatments for Neonatal Abstinence Syndrome. JAMA Pediatrics. 2019;173(3):234–43. doi: 10.1001/jamapediatrics.2018.5044 30667476

11. Reddy UM, Davis JM, Ren Z, Greene MF. Opioid Use in Pregnancy, Neonatal Abstinence Syndrome, and Childhood Outcomes: Executive Summary of a Joint Workshop by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, American College of Obstetricians and Gynecologists, American Academy of Pediatrics, Society for Maternal-Fetal Medicine, Centers for Disease Control and Prevention, and the March of Dimes Foundation. Obstet Gynecol. 2017;130(1):10–28. Epub 2017/06/09. doi: 10.1097/AOG.0000000000002054 28594753; PubMed Central PMCID: PMC5486414.

12. Wachman EM, Schiff DM, Silverstein M. Neonatal Abstinence Syndrome Advances in Diagnosis and Treatment. JAMA-J Am Med Assoc. 2018;319(13):1362–74. doi: 10.1001/jama.2018.2640 WOS:000429035900020. 29614184

13. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol. 2014;180(7):673–86. Epub 2014/08/26. doi: 10.1093/aje/kwu190 25150272.

14. Grossman M, Seashore C, Holmes AV. Neonatal Abstinence Syndrome Management: A Review of Recent Evidence. Rev Recent Clin Trials. 2017;12(4):226–32. doi: 10.2174/1574887112666170816144818 WOS:000415749200002. 28814260

15. Creanga AA, Berg CJ, Ko JY, Farr SL, Tong VT, Bruce FC, et al. Maternal Mortality and Morbidity in the United States: Where Are We Now? Journal of Women's Health. 2014;23(1):3–9. doi: 10.1089/jwh.2013.4617 24383493

16. Patrick SW, Dudley J, Martin PR, Harrell FE, Warren MD, Hartmann KE, et al. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135(5):842–50. doi: 10.1542/peds.2014-3299 25869370

17. Class QA, Rickert ME, Langstrom N, Lichtenstein P, D'Onofrio BM. Birth weight, physical morbidity, and mortality: A population-based sibling-comparison study. American Journal of Epidemiology. 2014;179:550–8. PubMed Central PMCID: PMCJournal in progress. doi: 10.1093/aje/kwt304 24355331

18. Class QA, Rickert ME, Larsson H, Lichtenstein P, D'Onofrio BM. Fetal growth and psychiatric and socioeconomic problems: population-based sibling comparison British Journal of Psychiatry. 2014;205(5):355–61. PubMed Central PMCID: PMCID in progress: NIHMSID: 602974. doi: 10.1192/bjp.bp.113.143693 25257067

19. D'Onofrio BM, Class QA, Rickert ME, Larsson H, Langstrom N, Lichtenstein P. Preterm birth and mortality and morbidity: A population-based quasi-experimental study. JAMA Psychiatry. 2013;70:1231–40. PubMed Central PMCID: PMC3823714. doi: 10.1001/jamapsychiatry.2013.2107 24068297

20. Quinn PD, Hur K, Chang Z, Krebs EE, Bair MJ, Scott EL, et al. Incident and long-term opioid therapy among patients with psychiatric conditions and medications: A national study of commercial health care claims. Pain. 2017;158(1):140–8. doi: 10.1097/j.pain.0000000000000730 27984526

21. Gustavsson A, Bjorkman J, Ljungcrantz C, Rhodin A, Rivano-Fischer M, Sjolund KF, et al. Pharmaceutical treatment patterns for patients with a diagnosis related to chronic pain initiating a slow-release strong opioid treatment in Sweden. Pain. 2012;153(12):2325–31. Epub 2012/09/05. doi: 10.1016/j.pain.2012.07.011 22944610

22. Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: Retrospective analysis. BMJ. 2017;356:j760. doi: 10.1136/bmj.j760 28292769

23. Fredheim OMS, Borchgrevink PC, Mahic M, Skurtveit S. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: A study from the Norwegian Prescription Database. Pain. 2013;154(11):2487–93. doi: 10.1016/j.pain.2013.07.033 24075311

24. Larochelle MR, Zhang F, Ross-Degnan D, Wharam JF. Trends in opioid prescribing and co-prescribing of sedative hypnotics for acute and chronic musculoskeletal pain: 2001–2010. Pharmacoepidemiology and Drug Safety. 2015;24(8):885–92. doi: 10.1002/pds.3776 25906971

25. Kobus AM, Smith DH, Morasco BJ, Johnson ES, Yang X, Petrik AF, et al. Correlates of higher-dose opioid medication use for low back pain in primary care. Journal of Pain. 2012;13(11):1131–8. doi: 10.1016/j.jpain.2012.09.003 23117108

26. Morales DR, Slattery J, Evans S, Kurz X. Antidepressant use during pregnancy and risk of autism spectrum disorder and attention deficit hyperactivity disorder: systematic review of observational studies and methodological considerations. BMC Medicine. 2018;16(1):6. doi: 10.1186/s12916-017-0993-3 29332605

27. Pourhoseingholi MA, Baghestani AR, Vahedi M. How to control confounding effects by statistical analysis. Gastroenterology and Hepatology From Bed to Bench. 2012;5(2):79–83. PMC4017459. 24834204

28. Rutter M. Psychosocial influences: Critiques, findings, and research needs. Development and Psychopathology. 2000;12:375–405. doi: 10.1017/s0954579400003072 11014744

29. Academy of Medical Sciences Working Group. Identifying the environmental causes of disease: How should we decide what to believe and when to take action? London: Academy of Medical Sciences; 2007.

30. Shadish WR, Cook TD, Campbell DT. Experimental and quasi-experimental designs for generalized causal inference. New York: Houghton Mifflin; 2002.

31. Statistics Sweden [cited 2019 Sep 23]. Available from: https://www.scb.se/en/.

32. Statistics Sweden. Multi-Generation Register 2009—A Description of Contents and Quality. Örebro, Sweden: 2010.

33. National Board of Health and Welfare. 4 years with the Prescribed Drug Register [in Swedish]. Stockholm: National Board of Health and Welfare, 2010.

34. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register—opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and drug safety. 2007;16(7):726–35. Epub 2006/08/10. doi: 10.1002/pds.1294 16897791.

35. National Board of Health and Welfare. The Swedish Medical Birth Register—A Summary of Content and Quality. Stockholm: National Board of Health and Welfare, 2003.

36. Cnattingius S, Ericson A, Gunnarskog J, Kallen B. A quality study of a medical birth registry. Scand J Soc Med. 1990;18(2):143–8. doi: 10.1177/140349489001800209 2367825.

37. National Board of Health and Welfare. Pregnancies, Deliveries and Newborn Infants—The Swedish Medical Birth Register 1973–2011, Assisted Reproduction, treatment 1991–2010 [in Swedish]. Stockholm: 2013.

38. National Board of Health and Welfare. Quality and Content in the Patient Register—Inpatient care discharges 1964–2007 and outpatient (specialized care) visits 1997–2007 [in Swedish]. Stockholm: National Board of Health and Welfare, 2009 2009-125–15.

39. WHO. International Classification of Diseases, World Health Organization WHO. Geneva1992.

40. BRÅ e. Kriminalstatistik 2010 [Criminal statistics]. In: Västerås, editor. 2011.

41. Fazel S, Grann M. The population impact of severe mental illness on violent crime. American Journal of Psychiatry. 2006;163(8):1397–403. doi: 10.1176/ajp.2006.163.8.1397 WOS:000239358800018. 16877653

42. Statistics Sweden. Education in Sweden 2009 2009 [updated February 21, 2014] [cited 2019 Sep 23]. Available from: http://www.scb.se/statistik/_publikationer/uf0527_2009a01_br_uf08br0901.pdf

43. LISA database [cited 2019 Sep 23]. Available from: http://www.scb.se/Pages/List____257743.aspx

44. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2014. Oslo: Author, 2013.

45. Abrahamsson T, Berge J, Ojehagen A, Hakansson A. Benzodiazepine, z-drug and pregabalin prescriptions and mortality among patients in opioid maintenance treatment-A nation-wide register-based open cohort study. Drug and alcohol dependence. 2017;174:58–64. Epub 2017/03/21. doi: 10.1016/j.drugalcdep.2017.01.013 28315808.

46. Hampp C, Gelperin K, Taylor L, Bird ST, Toh S, Sahin L, et al. Misclassification in Assessment of First Trimester In-utero Exposure to Drugs Used Proximally to Conception: the Example of Letrozole Utilization for Infertility Treatment. American Journal of Epidemiology. 2018;188(2):418–25. doi: 10.1093/aje/kwy237 30321259

47. Hagenfeldt K, Alton V, Axelsson O, Blennow M, Bojö F, Bygdeman M, et al. Routine ultrasound examination during pregnancy—summary in English. Stockholm: The Swedish Council on Health Technology Assessment (SBU). 1998.

48. Soderberg KC, Laflamme L, Moller J. Newly initiated opioid treatment and the risk of fall-related injuries. A nationwide, register-based, case-crossover study in Sweden. Cns Drugs. 2013;27(2):155–61. doi: 10.1007/s40263-013-0038-1 23345030

49. Quinn PD, Rickert ME, Franck J, Sariaslan A, Boersma K, Lichtenstein P, et al. Associations of mental health and family background with opioid analgesic therapy: a nationwide Swedish register-based study. Pain. 2019. Epub 2019/07/25. doi: 10.1097/j.pain.0000000000001643 31339870.

50. Sariaslan A, Langstrom N, D'Onofrio B, Hallqvist J, Franck J, Lichtenstein P. The impact of neighbourhood deprivation on adolescent violent criminality and substance misuse: a longitudinal, quasi-experimental study of the total Swedish population. International journal of epidemiology. 2013;42(4):1057–66. Epub 2013/09/26. doi: 10.1093/ije/dyt066 24062294; PubMed Central PMCID: PMC3780994.

51. Pearl J. Causality: Models, Reasoning and Inference. Cambridge: Cambridge University Press; 2000.

52. Luellen JK, Shadish WR, Clark MH. Propensity scores: an introduction and experimental test. Eval Rev. 2005;29(6):530–58. doi: 10.1177/0193841X05275596 16244051

53. Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: Historical foundations and contemporary application. Current Epidemiology Reports. 2015;2(4):221–8. doi: 10.1007/s40471-015-0053-5 26954351

54. Smith GD. Assessing intrauterine influences on offspring health outcomes: can epidemiological studies yield robust findings? Basic Clin Pharmacol Toxicol. 2008;102(2):245–56. doi: 10.1111/j.1742-7843.2007.00191.x 18226080

55. D'Onofrio BM, Class QA, Rickert ME, Sujan AC, Larsson H, Kuja-Halkola R, et al. Translational Epidemiologic Approaches to Understanding the Consequences of Early-Life Exposures. Behav Genet. 2016;46(3):315–28. Epub 2015/11/23. doi: 10.1007/s10519-015-9769-8 26590988; PubMed Central PMCID: PMC4860044.

56. Svendsen K, Borchgrevink PC, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: The use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliative Medicine. 2011;25(7):725–32. doi: 10.1177/0269216311398300 21378066

57. Handal M, Engeland A, Ronning M, Skurtveit S, Furu K. Use of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during, and after pregnancy: a population-based cohort study. European Journal of Clinical Pharmacology. 2011;67(9):953–60. doi: 10.1007/s00228-011-1030-7 WOS:000293790000011. 21484468